Leo Grady
Seminars
Tuesday 24th June 2025
Panel Discussion: From Consumer Success to Clinical Impact: How Direct-to-Consumer Microbiome Products Are Shaping Therapeutic Breakthroughs
4:30 pm
- Evaluating clinical trial strategies for direct-to-consumer microbiome products: costs, regulatory pathways, and scientific credibility
- Analyzing the economic viability of trial-based models in the DTC space: profitability, investor interest, and commercialization speed
- Navigating marketing and regulatory constraints for microbiome therapeutics in a consumer-driven landscape
Wednesday 25th June 2025
Leveraging AI & Big Data in Microbiome Drug Discovery
2:00 pm
- Analyzing gut microbiome data is incredibly challenging due to the wide variation in microbial ecosystems found in the gut and due to the incredible explosion of scientific papers linking the gut microbiome to various diseases and health conditions (now more than two thousand peer-reviewed studies per month in PubMed). For the first time, large language models (a form of AI) offer us the ability to synthesize all of the world’s scientific knowledge to fully analyze gut microbiome data for an individual.
- The extraction of the complete published scientific knowledge of the microbiome makes it possible to develop a microbiome digital twin that can be used to digitally simulate the effects of different interventions on a trial subject with a known microbiome and predict drug therapeutic efficacy prior to treatment in the trial
- This AI technology for both analysis and digital twinning unlocks new opportunities and avenues for drug targets, therapeutic development, clinical trial design, patient recruitment and biomarker development
